Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate

References

• World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99-58.html [last accessed 4 March 2006]
   Google Scholar
• US Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD, USA: FDA Division of Metabolic and Endocrine Drug Products, 1994. Available at: http://www.fda.gov/cder/guidance/osteo.pdf [last accessed 20 July 2006]
   Google Scholar
• Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018–26
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis [The Alendronate Phase III Osteoporosis Treatment Study Group]. New Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al.; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344: 333–40
   Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporosis Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
   PubMedGoogle Scholar
• Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757–64
   PubMed Web of Science ®Google Scholar
• Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporosis Int 2003;14:437–41
   PubMed Web of Science ®Google Scholar
• Walliser JA, Bolge SC, Sen SS. Patients’ preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry meeting, February 1–4, 2006, San Diego, CA, USA [abstract 213]
   Google Scholar
• Walliser J, Bolge S, Sen SS. Patients’ perception of importance of different attributes of osteoporosis medication: results from the PREFER-International study. European Calcified Tissue Society meeting, May 10–14, 2006, Prague, Czech Republic [abstract P464]
   Google Scholar
• Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949–60
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15: 792–8
   Google Scholar
• Akesson K, Beusterien K, Hebborn A, Leidy NK. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Osteoporosis Int 2005;16\(Suppl 4):P622–Su
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
   PubMed Web of Science ®Google Scholar
• Benhamou C, Licata AA, Devas V, et al. Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: the BALTO II study. European Calcified Tissue Society meeting, May 10–14, 2006, Prague, Czech Republic [abstract P350]
   Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11: 449–57
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42–5
   PubMedGoogle Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. May Clin Proc 2005;80: 856–61
   Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 2006;17:914–21
   PubMed Web of Science ®Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. European Calcified Tissue Society meeting, June 25–29, 2005, Geneva, Switzerland [abstract P610–Su]
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
   Google Scholar
• Cooper AL; on behalf of PERSIST Study Investigators. Improved patient persistence on once-monthly dosing regime plus patient support compared with a weekly dosing regime. International Osteoporosis Foundation, World Congress on Osteoporosis, June 2–6, 2006, Toronto, Canada [abstract P798MO]
   Google Scholar
• IMS database. January 2006
   Google Scholar
• Keen R, Jodar E, Iolascon G, et al. The clinical effectiveness of an osteoporosis treatment influences women’s preference more than dosing frequency. Curr Med Res Opin 2006 [accepted for publication]
   Google Scholar
• Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006;17:922–8
   PubMed Web of Science ®Google Scholar
• Ayanian JZ. Using administrative data to assess health care outcomes. Eur Heart J 1999;20:1689–91
   PubMed Web of Science ®Google Scholar
• Britton A, McKee M, Black N, et al. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998;2:1–124
   PubMedGoogle Scholar
• McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. Br Med J 1999;319:312–5
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Koay MA, Walker M, Corner A, et al. Improved patient education and support may enhance adherence to bisphosphonate therapy. European Calcified Tissue Society meeting, May 10–14, 2006, Prague, Czech Republic [abstract P480]
   Google Scholar